Clinical trials: Graft-Versus-Host Disease
Acute Graft vs Host Disease, Allogeneic Bone Marrow Transplantation
Pediatric GVHD Low Risk Steroid Taper Trial
The standard treatment for acute graft-vs-host disease (GVHD) is to suppress the activity of the donor immune cells using steroid medications such as prednisone.
- Conditions
- Acute Graft vs Host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects
- Trial name
- NCT05090384
- Testing
- Prednisone
- Where
- 11 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- John Levine
Graft vs Host Disease, Kidney Transplantation
Study Evaluating Sirolimus in Kidney Transplant Recipients
The purpose of this study is to compare the kidney function in patients who have received a transplanted kidney and were treated with the combination of sirolimus, daclizumab, mycophenolate and corticosteroids versus transplanted…
- Trial name
- NCT00195273
- Testing
- sirolimus, cyclosporine, mycophenolate mofetil
- Where
- 3 sites in Norway, Sweden
- Volunteers
- 61 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Persistent Corneal Epithelial Defect
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
This is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of cenegermin in inducing complete epithelial healing in participants…
- Trial name
- NCT07519902
- Testing
- Cenegermin, Vehicle
- Where
- 77 sites in United States, Argentina and 12 more
- Volunteers
- 150 people
- Sponsor
- Dompé Farmaceutici S.p.A
Graft Versus Host Disease
Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant
This phase I trial studies the side effects and best dose of donor regulatory T cells in treating patients with graft-versus-host disease affecting the liver or gastrointestinal organs (visceral) within 100 days (acute) after…
- Trial name
- NCT02526329
- Testing
- donor regulatory T lymphocytes, laboratory biomarker analysis
- Where
- United States
- Sponsor
- Everett Meyer
Chronic Graft Versus Host Disease, Acute Graft Versus Host Disease
Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease
This clinical trial evaluates the feasibility and effectiveness of a post-transplant dental cleaning for the prevention of chronic graft versus host disease (GVHD) in patients undergoing an allogeneic hematopoietic cell…
- Conditions
- Chronic Graft Versus Host Disease, Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
- Trial name
- NCT07535008
- Testing
- Dental Cleaning, Dental Plaque sampling
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Fred Hutchinson Cancer Center
Tinnitus, Subjective
Efficacy Study for Development and Use of Neurofeedback-trainings for Patients Suffering From Chronic Tinnitus
Chronic tinnitus affects about 10-15% of the population in industrialized countries. Investigations of the brain activity by using electroencephalography (EEG) showed that in localized regions of the hearing system brain activity…
- Trial name
- NCT02383147
- Testing
- Tomographic Neurofeedback, Non Tomographic Neurofeedback
- Where
- Switzerland
- Volunteers
- 52 people
- Sponsor
- University of Zurich
Schistosomiasis
Assessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic Schistosomiasis
The primary objective of this clinical investigation is to determine the percentage of travelers and migrants diagnosed with chronic schistosomiasis according to site-specific diagnostic practice who have active infection at the…
- Trial name
- SchistAct (NCT06873308)
- Testing
- UCP-LF CAA assay
- Where
- 8 sites in Belgium, Germany and 3 more
- Volunteers
- 278 people
- Sponsor
- IRCCS Sacro Cuore Don Calabria di Negrar
Acute-graft-versus-host Disease
Pharmacological Predictors of Successful Cyclosporine Acute GVHD Prophylaxis in Children Undergoing HSCT
The specific objectives of this study are: Primary: 1)To determine the relationship between cyclosporine AUC achieved prior to engraftment and severe aGVHD (grade III and IV) Secondary: 1.
- Trial name
- NCT02175615
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- Lee Dupuis
Lymphoma, Non-Hodgkin's Lymphoma
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
The purpose of this study is to determine the long-term (> 6 months) safety of PCI 24781 PO in subjects with lymphoma.
- Conditions
- Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin Disease, Multiple Myeloma
- Trial name
- NCT01149668
- Testing
- PCI-24781
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Pharmacyclics LLC.
Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
To evaluate the safety, efficacy and pharmacokinetics of nilotinib over time in the Ph+ chronic myelogenous leukemia (CML) in pediatric patients (from 1 to <18 years).
- Trial name
- DIALOG (NCT01844765)
- Testing
- nilotinib
- Where
- 36 sites in United States, France and 11 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye, Ocular Graft vs Host Disease
Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)
The objective of this study is to establish whether patients with dry eye disease (DED) are able to tolerate receiving Brimonidine: 0.15% eye drops two times a day for twelve weeks (primary tolerability objective) and to…
- Conditions
- Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction
- Trial name
- NCT02975557
- Testing
- Brimonidine 0.15%, Brimonidine 0.075%
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sandeep Jain, MD
Chronic Graft Versus Host Disease
Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease
This phase II trial studies how well ixazomib citrate works in treating patients with chronic graft-versus-host disease. Chronic graft-versus-host disease is a complication of a donor bone marrow or blood cell transplant, usually…
- Trial name
- NCT02513498
- Testing
- Ixazomib Citrate, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Graft Versus Host Disease, Malignant Hematologic Neoplasm
Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases
Evaluating the safety and effectiveness of a CD25 monoclonal antibody-based prophylactic acute graft-versus-host-disease (aGVHD) regimen following unrelated umbilical cord blood transplantation (UCBT) for malignant hematologic…
- Trial name
- NCT06480630
- Testing
- Basiliximab
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Anhui Provincial Hospital
Chronic Graft-versus-host-disease
A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD
This is a Phase 1/2, Open-label, Dose Escalation study to investigate axatilimab in participants with active chronic graft versus host disease (cGVHD).
- Trial name
- NCT03604692
- Testing
- axatilimab
- Where
- 11 sites in United States
- Volunteers
- 41 people
- Sponsor
- Syndax Pharmaceuticals
Graft vs Host Disease
A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease
This study was been conducted to evaluate the safety, tolerability, and activity of belumosudil (formerly known as KD025) in adult participants with chronic graft versus host disease (cGVHD).
- Trial name
- NCT02841995
- Testing
- Belumosudil (KD025)
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- Kadmon, a Sanofi Company
Bone Marrow Transplantation, Graft vs Host Disease
Toward Immune Biomarkers for Tolerance and GvHD in Humans
Graft-versus-Host Disease (GVHD), is the most frequent and severe complication of allogeneic hematopoietic stem cell transplantation (HSCT).
- Conditions
- Bone Marrow Transplantation, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
- Trial name
- BioGvHD (NCT02319226)
- Testing
- Transplantation from an HLA-identical sibling donor
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatitis C Infection
A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection
The purpose of this study is to compare the safety and tolerability of ascending doses of SB 9200 given for up to 14 days to subjects with chronic Hepatitis C infection.
- Trial name
- NCT01803308
- Testing
- SB9200
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 37 people
- Sponsor
- Syneos Health
Chronic Myeloid Leukemia
Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia
Ponatinib has shown to induce deeper molecular responses compared with imatinib. Therefore, ponatinib treatment could increase the proportion of patients who could discontinue treatment successfully.
- Trial name
- NCT04043676
- Testing
- Ponatinib
- Where
- 9 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Fundación Teófilo Hernando, Spain
Aplastic Anemia
Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant
This clinical trial is studying how well giving cyclophosphamide together with anti-thymocyte globulin followed by methotrexate and cyclosporine works in preventing chronic graft-vs-host disease (GVHD) in patients with severe…
- Trial name
- NCT00343785
- Testing
- cyclophosphamide, anti-thymocyte globulin, cyclosporine
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Fred Hutchinson Cancer Center
Myeloid Leukemia, Chronic
Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia
The first purpose of this study is to evaluate the persistence of the complete molecular remission in patients with Chronic Myeloid Leukemia after stopping imatinib treatment (determine by Reverse Transcription real-time…
- Trial name
- STIM (NCT00478985)
- Testing
- Imatinib ending
- Where
- 24 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.